Mar 11, 2024 / 04:40PM GMT
Daina Michelle Graybosch - Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst
Hi, everyone. Thank you for coming to the session. My name is Daina Graybosch. I and my team cover immuno-oncology and beyond here at Leerink Partners. And I'm really excited to have a great oncology conversation with Merck. We have Dr. Marjorie Green and Peter Dannenbaum here.
And I thought maybe we'd start. Dr. Green, you could give a bit of an intro to yourself because you're relatively new to Merck, and then we'll jump into some questions on oncology and Merck.
Marjorie C. Green - Merck & Co., Inc. - Senior VP & Head of Late-Stage Oncology - Global Clinical Development
Fantastic. Thanks, Daina. Really excited to be here and for the opportunity. So I have joined Merck in April of 2023. By training, I am a breast medical oncologist, so I'm a sub-subspecialist and was at MD Anderson for a long time on faculty there and then moved to industry and have had the pleasure to work at Genentech and then most recently at Seagen
Merck & Co Inc at Leerink Partners Global Biopharma Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot